Gardos G, Casey D E, Cole J O, Perenyi A, Kocsis E, Arato M, Samson J A, Conley C
Affective Disorders Program, McLean Hospital, Belmont, MA 02178.
Am J Psychiatry. 1994 Jun;151(6):836-41. doi: 10.1176/ajp.151.6.836.
The purpose of this study was to assess the long-term outcome of patients with tardive dyskinesia.
A group of 122 neuroleptic-treated Hungarian outpatients were assessed for tardive dyskinesia on the Abnormal Involuntary Movement Scale and the Tardive Dyskinesia Rating Scale by the same rater over a 10-year period.
Sixty-three of the patients received both 5- and 10-year follow-up assessments and are the subjects of this report. The overall prevalence of tardive dyskinesia in this group changed little over time; it was 30.2% at baseline, 36.5% at 5 years, and 31.7% at 10 years. However, there were changes in the tardive dyskinesia status of individual patients; 11 patients had remissions, and 12 who did not have tardive dyskinesia at the baseline assessment had developed it by the 10-year assessment. These two subgroups did not differ significantly on demographic and drug history variables. Outcome of tardive dyskinesia was not significantly related to neuroleptic treatment or to age.
The data of this 10-year follow-up study provide evidence for the long-term stability of tardive dyskinesia and for the feasibility of maintenance neuroleptic therapy for chronic psychotic patients who have tardive dyskinesia.
本研究旨在评估迟发性运动障碍患者的长期预后。
一组122名接受抗精神病药物治疗的匈牙利门诊患者在10年期间由同一名评估者使用异常不自主运动量表和迟发性运动障碍评定量表对迟发性运动障碍进行评估。
63名患者接受了5年和10年的随访评估，是本报告的研究对象。该组迟发性运动障碍的总体患病率随时间变化不大；基线时为30.2%，5年时为36.5%，10年时为31.7%。然而，个体患者的迟发性运动障碍状态有所变化；11名患者病情缓解，12名在基线评估时没有迟发性运动障碍的患者在10年评估时出现了该疾病。这两个亚组在人口统计学和用药史变量方面没有显著差异。迟发性运动障碍的预后与抗精神病药物治疗或年龄没有显著关系。
这项10年随访研究的数据为迟发性运动障碍的长期稳定性以及对患有迟发性运动障碍的慢性精神病患者进行维持性抗精神病药物治疗的可行性提供了证据。
